Spexis Overview

  • Year Founded
  • 1996

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 28

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 11

  • Investments
  • 1

Spexis General Information

Description

Developer of biopharmaceutical therapies for rare diseases and oncology indications based in Allschwil, Switzerland. The company develops macrocyclic molecule-based therapeutics and drug discovery platforms, including inhaled therapies for cystic fibrosis, anti-infective treatments, oncology drug candidates, and other clinical and preclinical programs, enabling healthcare providers and patients to access innovative treatments targeting difficult-to-treat diseases.

Contact Information

Website
www.spexisbio.com
Formerly Known As
Polyphor
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Corporate Office
  • Hegenheimermattweg 125
  • 4123 Allschwil
  • Switzerland
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Acquirer
Cyaris
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Hegenheimermattweg 125
  • 4123 Allschwil
  • Switzerland

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Spexis Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Spexis‘s full profile, request access.

Request a free trial

Spexis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of biopharmaceutical therapies for rare diseases and oncology indications based in Allschwil, Switzerland. The
Drug Discovery
Allschwil, Switzerland
28 As of 2022

Singapore, Singapore
 

Cambridge, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Spexis Competitors (55)

One of Spexis’s 55 competitors is KBP Biosciences, a Venture Capital-Backed company based in Singapore, Singapore.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
KBP Biosciences Venture Capital-Backed Singapore, Singapore
Healx Venture Capital-Backed Cambridge, United Kingdom
Relay Therapeutics Formerly VC-backed Cambridge, MA
Molecular Partners Formerly VC-backed Zurich, Switzerland
Zealand Pharma Formerly VC-backed Soborg, Denmark
You’re viewing 5 of 55 competitors. Get the full list »

Spexis Patents

  • 511

    Total Documents Applications and Grants

  • Total Patents Families

  • 244

    Granted

  • 16

    Pending

  • Expiring in next 12 mo

Spexis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025068348-A1 Pharmaceutical combination of cxcr4 and pd-1 inhibitors for treating cancer Inactive 27-Sep-2023
WO-2025068346-A1 Pharmaceutical combination of cxcr4, pd-1 and fak inhibitors for treating cancer Inactive 27-Sep-2023
WO-2024061946-A2 High dose applications of a peptide cxcr4 inhibitor Inactive 20-Sep-2022
WO-2024061946-A3 High dose applications of the peptide cxcr4 inhibitor balixafortide Inactive 20-Sep-2022
US-20240336654-A1 Antimicrobial peptidomimetics Pending 05-Aug-2021 C07K7/08
To view Spexis’s complete patent history, request access »

Spexis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Spexis Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Spexis‘s full profile, request access.

Request a free trial

Spexis Acquisitions (1)

Spexis’s most recent deal was a Merger/Acquisition with EnBiotix. The deal was made on 29-Dec-2021.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
EnBiotix 29-Dec-2021 Merger/Acquisition Drug Discovery
To view Spexis’s complete acquisitions history, request access »

Spexis FAQs

  • When was Spexis founded?

    Spexis was founded in 1996.

  • Where is Spexis headquartered?

    Spexis is headquartered in Allschwil, Switzerland.

  • What is the size of Spexis?

    Spexis has 28 total employees.

  • What industry is Spexis in?

    Spexis’s primary industry is Drug Discovery.

  • Is Spexis a private or public company?

    Spexis is a Private company.

  • What is Spexis’s current revenue?

    The current revenue for Spexis is .

  • How much funding has Spexis raised over time?

    Spexis has raised $227M.

  • Who are Spexis’s investors?

    Bachem Feinchemikalien, BioBac, BioMedPartners, CARB-X, and are 5 of 16 investors who have invested in Spexis.

  • Who are Spexis’s competitors?

    KBP Biosciences, Healx, Relay Therapeutics, Molecular Partners, and Zealand Pharma are some of the 55 competitors of Spexis.

  • Who acquired Spexis?

    Spexis was acquired by Cyaris.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process